



OPEN ACCESS

EDITED BY

Jianqiang Xu,
Dalian University of Technology, China

REVIEWED BY

Chandrabose Selvaraj,
Alagappa University, India

*CORRESPONDENCE

T. S. Anitha,
✉ tsanitha6@pondiuni.ac.in

†PRESENT ADDRESS

T. S. Anitha, Department of Biochemistry and
Molecular Biology, Pondicherry University,
Puducherry, India

RECEIVED 16 October 2023

ACCEPTED 22 December 2023

PUBLISHED 09 January 2024

CITATION

Kuduvalli SS, Daisy PS, Vaithy A,
Purushothaman M, Muralidharan AR, Agiesh KB,
Mezger M, Antony JS, Subramani M, Dubashi B,
Biswas I, Guruprasad KP and Anitha TS (2024),
Corrigendum: A combination of metformin and
epigallocatechin gallate potentiates glioma
chemotherapy *in vivo*.
Front. Pharmacol. 14:1322332.
doi: 10.3389/fphar.2023.1322332

COPYRIGHT

© 2024 Kuduvalli, Daisy, Vaithy,
Purushothaman, Muralidharan, Agiesh, Mezger,
Antony, Subramani, Dubashi, Biswas,
Guruprasad and Anitha. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/).
The use, distribution or reproduction in other
forums is permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original publication in this
journal is cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Corrigendum: A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy *in vivo*

Shreyas S. Kuduvalli¹, Precilla S. Daisy¹, Anandraj Vaithy²,
Mugilarasi Purushothaman³,
Arumugam Ramachandran Muralidharan^{4,5}, Kumar B. Agiesh¹,
Markus Mezger⁶, Justin S. Antony⁶, Madhu Subramani⁷,
Biswajit Dubashi⁸, Indrani Biswas¹, K. P. Guruprasad⁹ and
T. S. Anitha^{1*†}

¹Mahatma Gandhi Medical Advanced Research Institute (MGMARI), Sri Balaji Vidyapeeth University (Deemed to-be University), Puducherry, India, ²Department of Pathology, Mahatma Gandhi Medical College and Research Institute, Sri Balaji Vidyapeeth University (Deemed to-be University), Puducherry, India, ³Department of Pharmacy, National University of Singapore, Singapore, Singapore, ⁴Department of Visual Neurosciences, Singapore Eye Research Institute, Singapore, Singapore, ⁵Eye-APC, Duke-NUS Medical School, Singapore, Singapore, ⁶Department of General Paediatrics, Haematology/Oncology, University Children's Hospital Tübingen, Tübingen, Germany, ⁷ScirosBio (FZC), SRTI Park, Sharjah, United Arab Emirates, ⁸Department of Medical Oncology, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER), Puducherry, India, ⁹Department of Ageing Research, Manipal School of Life Sciences, MAHE, Manipal, Karnataka, India

KEYWORDS

glioma, metformin, epigallocatechin gallate (EGCG), molecular docking, quantum mechanics (QM), ROS-reactive oxygen species, PI3K/Akt/mTOR pathway

A Corrigendum on

A combination of metformin and epigallocatechin gallate potentiates glioma chemotherapy *in vivo*

by Kuduvalli SS, Daisy PS, Vaithy A, Purushothaman M, Ramachandran Muralidharan A, Agiesh KB, Mezger M, Antony JS, Subramani M, Dubashi B, Biswas I, Guruprasad KP and Anitha TS (2023). *Front. Pharmacol.* 14:1096614. doi: 10.3389/fphar.2023.1096614

In the published article, there was an error in [Table 1](#). The values of drug doses were inadvertently misrepresented during the final assembly of [Table 1](#). The corrected [Table 1](#) and its caption appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

TABLE 1 The concentration of each drug used in the treatment of animals both individually and in combination.

Groups	Drugs	Dosage (mg/kg body weight)
Group II	Tumor control	NA
Group III	T	50
Group IV	M	80
Group V	E	150
Group VI	TM	50 + 80
Group VII	TE	50 + 150
Group VIII	ME	80 + 150
Group IX	TME	50 + 80 + 150